1
Clinical Trials associated with PEP-223/CoVaccine HT(Pepscan Therapeutics)A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.
100 Clinical Results associated with PEP-223/CoVaccine HT(Pepscan Therapeutics)
100 Translational Medicine associated with PEP-223/CoVaccine HT(Pepscan Therapeutics)
100 Patents (Medical) associated with PEP-223/CoVaccine HT(Pepscan Therapeutics)
100 Deals associated with PEP-223/CoVaccine HT(Pepscan Therapeutics)